drugset / Trial / NCT05071937
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.
Timeline
- Start
- 2023-04-21
- Primary completion
- 2033-11-30
- Completion
- 2034-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talazoparib | Small molecule | 0.75 mg | Oral |
| Subject | ZEN-3694 | Small molecule | 48 mg | Oral |